Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa (Q34290150)

1 August 2017

Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa (English)

1 reference

1 August 2017

0 references

Pseudomonas aeruginosa

0 references

1 reference

4

Jean-Louis Vincent

1 reference

1 August 2017

Brice Layeux

1

1 reference

1 August 2017

Fabio Silvio Taccone

series ordinal

2

1 reference

1 August 2017

David Fagnoul

series ordinal

3

1 reference

1 August 2017

Frédérique Jacobs

series ordinal

5

1 reference

1 August 2017

language of work or name

English

0 references

publication date

7 September 2010

1 reference

Antimicrobial Agents and Chemotherapy

1 August 2017

1 reference

1 August 2017

54

1 reference

1 August 2017

11

1 reference

1 August 2017

4939-4941

1 reference

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Prospects for the next anti-Pseudomonas drug

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Suboptimal aminoglycoside dosing in critically ill patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Back to the future: using aminoglycosides again and how to dose them optimally

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Clinical pharmacokinetics during continuous haemofiltration

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976156

28 October 2018

Identifiers

DOI

10.1128/AAC.00441-10

1 reference

1 August 2017

1 reference

1 August 2017

1 reference